Staedtisches Klinikum Dresden
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Staedtisches Klinikum Dresden, the clinical trial portfolio focuses on cardiovascular diseases, with studies centered on major conditions such as acute myocardial infarction, ischemic stroke, and atrial fibrillation. The research is aimed at improving prevention and treatment options for people at risk of serious heart- and brain-related complications.
- Testing a new therapy for people recovering from myocardial infarction, with attention to efficacy, safety, and the most promising treatment approach.
- Evaluating a treatment strategy to help prevent ischemic stroke after a recent stroke or high-risk transient ischemic attack, while also examining bleeding risk.
- Comparing a study treatment with an established option for atrial fibrillation to reduce the chance of stroke or systemic embolism and assess overall safety.
These studies reflect a strong interest in better thrombosis prevention, safer anticoagulant strategies, and improved outcomes for patients with high-risk cardiovascular conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 10 therapeutic areas and 15 of 60 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 60 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG3trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Staedtisches Klinikum Dresden
lock Showing 1 of 37 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | May 2019 | Jul 2025 |
IMP list
lock Showing 1 of 60 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 5 | Unknown | 2016-11-07 | 2025-12-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.